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ABSTRACT
Objective Estimates of cancer risk and the effects of
surveillance in Lynch syndrome have been subject to
bias, partly through reliance on retrospective studies.
We sought to establish more robust estimates
in patients undergoing prospective cancer surveillance.
Design We undertook a multicentre study of patients
carrying Lynch syndrome-associated mutations
affecting MLH1, MSH2, MSH6 or PMS2. Standardised
information on surveillance, cancers and outcomes
were collated in an Oracle relational database and
analysed by age, sex and mutated gene.
Results 1942 mutation carriers without previous cancer
had follow-up including colonoscopic surveillance for
13 782 observation years. 314 patients developed cancer,
mostly colorectal (n=151), endometrial (n=72) and ovarian
(n=19). Cancers were detected from 25 years onwards in
MLH1 and MSH2 mutation carriers, and from about
40 years in MSH6 and PMS2 carriers. Among ﬁrst cancer
detected in each patient the colorectal cancer cumulative
incidences at 70 years by gene were 46%, 35%, 20% and
10% for MLH1, MSH2, MSH6 and PMS2 mutation carriers,
respectively. The equivalent cumulative incidences for
endometrial cancer were 34%, 51%, 49% and 24%; and
for ovarian cancer 11%, 15%, 0% and 0%. Ten-year
crude survival was 87% after any cancer, 91% if the ﬁrst
cancer was colorectal, 98% if endometrial and 89% if
ovarian.
Conclusions The four Lynch syndrome-associated
genes had different penetrance and expression.
Colorectal cancer occurred frequently despite
colonoscopic surveillance but resulted in few deaths.
Using our data, a website has been established at
http://LScarisk.org enabling calculation of cumulative
cancer risks as an aid to genetic counselling in Lynch
syndrome.
Signiﬁcance of this study
What is already known on this subject?
▸ Inherited colorectal cancer may be caused
by mismatch repair gene mutations and is
then commonly referred to as Lynch
syndrome.
▸ Lynch syndrome is under-recognised and
results in about 0.1% of the population
having a signiﬁcantly increased risk of
early onset colorectal, endometrial and
ovarian cancer.
▸ Endoscopic surveillance with removal of
precursor adenomas is recommended to
prevent colorectal cancer.
What are the new ﬁndings?
▸ This is the ﬁrst comprehensive prospective
study to provide empirically observed data
on colorectal cancer incidence and survival
in Lynch syndrome.
▸ Colorectal cancer occurred despite
colonoscopic surveillance with removal of
adenomas.
▸ Colonoscopic surveillance with early
detection and treatment of invasive
colorectal cancer was associated with
excellent survival. Survival after ﬁrst
endometrial or ovarian cancer was also
excellent.
▸ Revised estimates of the different
penetrance and expression patterns in
carriers of MLH1, MSH2, MSH6 and PMS2
mutations.
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INTRODUCTION
Lynch syndrome (LS) is associated with a high probability of GI,
gynaecological and other cancers. It is caused by inherited muta-
tions affecting any of four DNA mismatch repair (MMR) genes,
MSH2, MLH1, PMS2 or MSH6, or by a deletion in the EPCAM
gene, which leads to methylation of the adjacent MSH2 pro-
moter. It is an under-recognised condition accounting for about
1–3% of colorectal cancers (CRCs) in the population.1 To date,
most LS patients have been identiﬁed following investigation
because of their family or personal histories of multiple and/or
early-onset cancers.
Carriers of pathogenic MLH1, MSH2, MSH6 or PMS2 muta-
tions require reliable information about their future cancer risk
so that they can be offered appropriately targeted surveillance,
but published risk estimates are extremely variable. One obvious
factor is reliance on retrospective data. Another is the impact of
initial selection criteria for molecular testing. In clinical practice,
these have included the Amsterdam I or Amsterdam II criteria,
the Bethesda guidelines or simply age at cancer diagnosis.
Previous estimates of the cumulative risk at 70 years for CRC in
MLH1 or MSH2 mutation carriers range from 22% to 74%.
Mutations in MSH6 and PMS2 genes have lower penetrance and
different patterns of expression: MSH6 mutation carriers are
thought to have a high risk of endometrial cancer, similar to
that in MSH2 mutation carriers, but lower risks of CRC. For a
comprehensive and updated overview of literature, see two
recently published reviews by us and others.1 2
Colonoscopy enables the identiﬁcation and removal of preinva-
sive neoplasia or early cancers in the absence of symptoms, and is
the mainstay of secondary prevention in LS patients. Although
adenoma removal is considered to represent a surrogate for the
prevention of CRC and death, the evidence supporting this
assumption in LS is controversial.1–11
The European ‘Majorca group’ (http://mallorca-group.eu) and
colleagues in the International Society for Gastrointestinal
Hereditary Tumours (http://insight-group.org) have developed a
pooled prospective database of LS mutation carriers to better
characterise their cancer risks and the effects of interventions.
This ﬁrst report focuses on the cumulative incidence of ﬁrst
cancers and associated survival.
PATIENTS AND METHODS
The LS prospective database
Data were stored and organised as an Oracle relational database
adapting the core structure of CGEN.12 This structure has the
capability for later addition of other information and classes of
information to the patients already ﬁled and for inclusion of
new patients. Data were manipulated by TOAD inside Oracle
and exported by TOAD to SYSTAT13 and Excel for further
manipulations and statistical calculations.
The variables used for this ﬁrst report were age at inclusion
for follow-up, gender, age at most recent observation, age at
death, mutated gene, age at diagnosis of any cancer, age at com-
plete surgical removal of organs and which preventive modal-
ities had been applied. Cancer diagnoses were scored by using
the ﬁrst three positions in the International Classiﬁcation of
Disease, ninth revision system. Ages were scored as integers.
Patients and interventions
Each centre had identiﬁed each patient to be at increased risk
of CRC according to internationally recognised guidelines1 2 or
local adaptations of these. Patients had then been subject
to follow-up by colonoscopy and modalities for early detection
of endometrial and ovarian cancer, and mutational analysis of the
MMR genes. All patients in this study were proven or obligate
carriers of pathogenic mutations as judged by the reporting
centre in the MLH1, MSH2, MSH6 or PMS2 genes at the time of
reporting. EPCAM mutations that lead to methylation of the adja-
cent MSH2 promoter were included and scored as MSH2 muta-
tions. The mutations were assumed to be germline, regardless of
when they were identiﬁed. All mutations reported in the 1942
patients were searched for in the Leiden open variant database
(LOVD) database (http://chromium.lovd.nl/LOVD2/colon_cancer/
) during October 2015: 1310 patients (67%) had pathogenic
(class 5) mutations, 28 patients (1%) had probably pathogenic
(class 4) mutations and the remaining 604 were not reported in
LOVD.
All analysed observations were prospective, commencing
when the patients were subjected to their ﬁrst prospectively
planned colonoscopy after being identiﬁed as at risk for colon
cancer. For the purpose of this report, cases with any cancer
prior to or at the same age as ﬁrst colonoscopy (prevalent
cancers) were excluded, as were all cases with <1 year of pro-
spective observation time. This was done to avoid selection bias
based on ascertainment and to ensure that no patient had any
sign or symptom of cancer at inclusion.
The surveillance guidelines included follow-up aimed at diag-
nosis of colorectal adenomas or early CRC and in many centres
endometrial cancer and ovarian cancer, as well as cancer aware-
ness for all cancers known to be associated with LS. Surveillance
and management guidelines have changed over time, and collab-
orating centres were subject to local/national decisions on how
to practise at different times. None of these variations were
used as variables in the present study. A detailed, referenced
description of follow-up and compliance is provided in online
supplementary table S2. The table and the references included
there show that from the outset the reporting centres used dif-
ferent intervals between colonoscopies, but that from around
1996 onwards all except for the Finnish centre followed the
emerging international guidelines advocating a 2-year interval
or less. Intervals between gynaecological examinations were in
general shorter. As previously published in the references given
in the table, all visible adenomas at colonoscopies were
removed. The references also show that precursor lesions were
less frequently found in the endometrium or ovaries. In short,
secondary prevention of colon cancer by identifying and remov-
ing precursor/early lesions was found to be promising, while
this was not the case for endometrial and ovarian cancer. In
consequence, all centres continued the colonoscopic surveil-
lance, while some advised prophylactic hysterectomy and
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ The results validate the continued use of colonoscopy
to prevent colorectal cancer death.
▸ Very high cure rate after endometrial and ovarian cancer
may call into question the place of risk reducing
oophorectomy and/or hysterectomy.
▸ MSH6 and possibly PMS2 mutation carriers have low
cancer risk before 40 years of age.
▸ Individual risk estimation should be based on mutated
gene, gender and age.
Colon
465Møller P, et al. Gut 2017;66:464–472. doi:10.1136/gutjnl-2015-309675
group.bmj.com on March 28, 2017 - Published by http://gut.bmj.com/Downloaded from 
oophorectomy to prevent gynaecological cancers. All patients
reported to the database had complete data sets, and there were
no missing values.
Some centres had previously reported the observed incidence
of cancer in their series but with different methods to those
used in this report.3–11 One group had reported previously on
survival.4 The intention of this report was to compile all infor-
mation available on prospectively observed outcomes in LS
patients without previous cancer and patients who were previ-
ously reported are included in the current report.
Annual and cumulative incidence rates
Each patient was observed from age at inclusion to age at last
observation or age at ﬁrst cancer, whichever came ﬁrst. Each
patient was counted only once, irrespective of how many syn-
chronous cancers the patient might have had as ﬁrst cancers.
Cancers that occurred after the ﬁrst cancer were not considered
in this study. Sine surveillance before 25 years and after 70 years
of age is not speciﬁed in current management guidelines and is
inconsistent in practice, annual incidence rates (AIRs) outside
25–70 years were not calculated. For each patient, the numbers
of years observed in each 5-year interval from 25 to 70 years of
age were counted. All ﬁrst cancers were scored according to age
at diagnosis. The AIR for a given age group was derived by div-
iding the number of cancers observed by the sum of observation
years in that age group.
Cumulative incidences for gynaecological cancers and prostate
cancers were considered for appropriate genders separately, and
observation time was censored at hysterectomy and oophorec-
tomy when considering incidences for such cancers separately.
Cumulative incidence, denoted by Q, was computed starting
at age 25, assuming zero incidence before age 25, using the
formula Q(age)=Q(age−1)+[1−Q(age−1)]·AIR(age), where AIR
(age) is the AIR as estimated from the corresponding 5-year
interval.
SE for AIR was estimated as SEAIR=sqrt[AIR·(1−AIR)/Yrs],
where Yrs denotes the number of observation years in the
5-year age group for which AIR is estimated. For cumulative
incidence, the hazard rate H=−ln[1−AIR] was used with SE
estimated SEH=SEAIR/(1−AIR). The SE, denoted by SEQ, of
the cumulative incidence Q(age) up to the given age is com-
puted in two steps. First, for each 5-year age interval, having
hazard rate H with SE SEH, the contribution to the cumulative
hazard from that interval is N·H with SE N·SEH, where N is
the number of years from that 5-year interval: for example, the
cumulative incidence up to age 32 contains all 5 years from the
25–29 age interval, but only 3 years from the 30–34 age inter-
val. The accumulated hazard CH is computed by adding the
N·H values across age intervals, while the corresponding SE,
SECH, is found by setting SECH2 equal to the sum of (N·SEH)
across age intervals. The accumulated hazard rate CH should
now equal −ln[1−Q] with Q as computed above, while the SE
of the cumulative incidence is computed as SEQ=SECH(1−Q).
We estimated 95% CIs as AIR±1.96 SEAIR and Q±1.96 SEQ.
Survival
Follow-up continued after the occurrence of ﬁrst cancers, and
all patients were either reported to be alive or validated to be
alive in population register on the day each patient was cen-
sored. Crude survival was calculated by the Kaplan–Meier algo-
rithm as time from ﬁrst cancer to last observation/death. Cancer
stages at diagnosis and causes of death were not considered in
this report.
RESULTS
Patients included and cancers diagnosed
In total, 1942 MMR mutation carriers were included: 944
MLH1, 616 MSH2, 305 MSH6 and 77 PMS2. Of these, 1057
were females and 885 were males. They were observed for a
total of 13 782 years (mean observation time 7.1 years), includ-
ing 6518 male and 7264 female observation years. Countries of
origin are detailed in table 1.
Mean ages at inclusion were 35.6 years for MLH1 mutation
carriers, 37.7 years for MSH2 mutation carriers, 43.0 years for
MSH6 mutation carriers and 47.1 years for PMS2 carriers.
Observation years were 7954 for MLH1 mutation carriers,
4021 MSH2, 1555 MSH6 and 313 for PMS2. Details when
stratifying on both gene and gender are given in table 1. The
numbers were considered sufﬁcient to stratify the ﬁndings on
gender, mutated gene, 5-year age cohorts and cancers in speciﬁc
organs. Although the numbers of PMS2 mutation carriers were
limited, they are included in all results presented.
Cancers diagnosed
Among the 1942 patients, 314 had prospectively identiﬁed ﬁrst
cancers (table 2), of which 151 were colorectal, 72 endometrial
and 19 ovarian. Of note, 21 patients had two synchronous ﬁrst
cancers.
In total, 186 females had had their uterus removed and
153 had had removal of the ovaries prior to any cancer diag-
nosis, reducing observations years when calculating the AIR
for endometrial and ovarian cancer (see online supplementary
table S1).
Table 1 Numbers of patients included, observation years, mean
observation years and mean age at inclusion for total series, by
country of origin and by gene and gender
All
Number Obs_years
Mean_obs_years
(range)
Mean_age_inclusion
(range)
1942 13 782 7.1 (1–33) 37.8 (10–84)
By country of origin
Finland 624 5399 8.6 (1–30) 36.1 (18–84)
Denmark 347 1852 5.3 (1–17) 39.6 (17–73)
Italy 167 1444 8.6 (1–33) 34.0 (10–65)
Norway 191 1309 6.9 (1–20) 38.4 (18–70)
The UK 195 990 5.1 (1–16) 40.0 (19–75)
Sweden 102 892 8.7 (1–20) 39.3 (18–81)
Australia 77 701 9.1 (1–29) 34.5 (19–56)
Holland 114 575 5.0 (1–28) 42.1 (19–78)
Germany 54 321 5.9 (1–26) 38.8 (20–72)
Spain 66 299 4.5 (1–14) 40.0 (18–75)
By gene and gender
MLH1
Females 514 4113 8.0 (1–33) 36.1 (18–84)
Males 430 3815 8.9 (1–30) 35.1 (10–81)
MSH2
Females 325 2100 6.5 (1–30) 37.9 (17–73)
Males 291 1895 6.5 (1–26) 37.5 (15–70)
MSH6
Females 170 846 5.0 (1–16) 43.1 (19–79)
Males 135 701 5.2 (1–28) 42.6 (10–72)
PMS2
Females 48 205 4.3 (1–20) 45.9 (24–78)
Males 29 107 3.7 (1–12) 48.2 (26–75)
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Cancer incidences
Calculated cumulative incidence for any cancer at age 70 years
was 75% in females and 58% in males. This sex difference was
evident from 50 years of age onwards. Sex-speciﬁc cumulative
cancer incidence is detailed in table 3.
The calculated cumulative cancer incidence by age 70 years
was high in MLH1 and MSH2 (72%) carriers and lower (at bor-
derline signiﬁcance) in MSH6 (54%) and PMS2 (18%) carriers.
The calculated cumulative incidence of cancer at age 70 years
for LS patients from different current ages onwards and differ-
ent mutated MMR genes are given in table 4.
Figure 1 shows the calculated complete distributions of time
to any ﬁrst cancer from 25 to 70 years of age by gene.
Table 5 shows cumulative cancer incidences from 25 years to
different greater ages by mutated MMR gene, cancer type and
gender. CRC cumulative incidence was high in MLH1 (46%)
and MSH2 (35%) mutation carriers, lower in MSH6 (20%) and
lower PMS2 (10%) mutation carriers. Endometrial cancer cumu-
lative incidence was high for MLH1 (34%), MSH2 (51%) and
MSH6 (49%) mutation carriers, and this cancer was also fre-
quent in older female PMS2 mutation carriers (24%). Ovarian
cancer was only identiﬁed in MLH1 (11%) and MSH2 (14%)
mutation carriers and most cases were diagnosed before age 50.
Upper GI and urinary tract cancers were infrequent and mostly
diagnosed after age 60. In all, cancers were frequently seen in
MLH1 and MSH2 mutation carriers from 25 years onwards but
not before 40 years in MSH6 and PMS2 mutation carriers.
Figures 2 and 3 show the calculated complete cumulative dis-
tributions from 25 to 70 years of age for CRC and endometrial
cancer, respectively, as the ﬁrst cancer by gene, corresponding
with the rows for CRC and endometrial cancer in table 5. To
facilitate genetic counselling and clinical practice, an interactive
website providing the complete distributions of all cancer
groups in table 5 from any age selected by the user and counting
to any greater age is available at http://www.lscarisk.org.
Time since last colonoscopy to CRC
Table 6 demonstrates time since last colonoscopy in the 145
cases with CRC. Mean time since last colonoscopy was
31.8 months, median 27 months and range 7–123 months.
Considering 2-year and 3-year interval between colonoscopies
as compliant with protocol if interval <2.5 and 3.5 years,
respectively, 84 cases (58%) were diagnosed within 2.5 since last
colonoscopy and 115 (79%) within 3.5 years.
Survival
Overall 5-year and 10-year survival were excellent, reﬂecting
survival for the most frequent cancers, CRC and endometrial
cancer (table 7). Ovarian cancer survival also appeared to be
excellent in LS patients, although the small number of cases
adds uncertainty to the observation. A majority of patients also
achieved 10-year survival of upper GI and urinary tract cancers,
although survival rates were not as good as for the other
cancers.
DISCUSSION
Our study was designed to answer three critical clinical ques-
tions in a large cohort of LS mutation carriers participating in
surveillance programmes: what is the cumulative risk by age to
ﬁrst cancer, in which organs are ﬁrst cancers most likely to
occur, and what are the outcomes for these cancers? It is essen-
tial that once identiﬁed LS patients are offered reliable estimates
of their future cancer risk and appropriate, individualised sur-
veillance. This is the ﬁrst study to present prospective empirical
observations from multiple centres and including sufﬁcient
numbers to meet these needs. This study reports time to ﬁrst
cancer (penetrance of the mutated genes) and survival after ﬁrst
cancer diagnosed. As the database is expanded, we will later
examine time to next cancer in those surviving ﬁrst cancer.
We show that cumulative incidence of any cancer at age
70 years is high for all MMR gene mutation carriers, and
slightly higher for females (75%) than males (58%). The cumu-
lative incidences were 72% for MLH1 and MSH2 mutation
Table 2 First cancers prospectively diagnosed by International
Classification of Disease, ninth revision (ICD-9) diagnoses, groups of
diagnoses and stratified on gender in Lynch syndrome (LS) patients
without prior or prevalent cancer at first colonoscopy
Group ICD-9 Organ Females Males Total
Colorectal cancers 153 Colon 59 72 131
154 Rectum/sigmoid 10 10 20
Endometrial and
ovarian cancers
182 Endometrium 72 72
183 Ovary 19 19
Upper GI cancers 151 Stomach 3 5 8
152 Duodenum 3 3 6
156 Biliary duct/gall
bladder
4 1 5
157 Pancreas 3 2 5
Urinary tract cancers 188 Urinary bladder 4 4
189 Kidney/ureter 6 7 13
Other LS or possibly
LS cancers
173* Skin* 6 6 12
174 Breast 15 15
191 Brain 1 1
185 Prostate 6 6
Other cancers 150 Oesophagus 1 1
159 Abdominal
unspecified
1 1
160 Nose 1 1
161 Larynx 1 1 2
162 Trachea 1 1
170 Osteosarcoma 1 1 2
172 Melanoma 2 2
180 Cervix 1 1
186 Testes 1 1
193 Thyroid 1 1
194 Neuroendocrine 2 2
202 Lymphoma 1 1
204 All/cll 1 1
208 Leukaemia
unspecified
1 1
Any cancer 208 127 335
*Includes both epithelial skin cancer that is often not reported, and sebaceous gland
invasive cancer. This specific diagnosis may not have been uniformly reported from
the different centres.
Table 3 Calculated sex-specific cumulative cancer incidences at
40, 50, 60 and 70 years for Lynch syndrome (LS) patients in the
total series in LS patients without prior or prevalent cancer at first
colonoscopy
Age
Cumulative incidence any cancer by age and gender
(95% CI)
Females Males
40 15% (10.3 to 19.9) 14% (9.2 to 18.8)
50 40% (34.4 to 46.0) 33% (27.1 to 39.4)
60 60% (54.6 to 66.2) 50% (42.7 to 56.7)
70 75% (68.7 to 81.3) 58% (49.9 to 65.7)
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carriers but lower in MSH6 (52%) and PMS2 (18%) mutation
carriers. MSH6 and PMS2 carriers developed no cancers before
40 years of age. However, the lower number of MSH6 and
PMS2 mutation carriers studied made the risk estimates for
these genes less certain, particularly at younger ages.
Despite the screening colonoscopy carried out, CRC was the
most frequent ﬁrst cancer observed and had a cumulative inci-
dence at age 70 of 46% in MLH1 mutation carriers, and 35%
in MSH2 mutation carriers with lower incidence for carriers of
mutations in MSH6 and PMS2. The results for CRC conﬁrmed
that colonoscopy fails to prevent a substantial number of CRCs
as previously reported.3–10 Retrospective studies have provided
with different estimates of cancer incidence mostly without
colonoscopic surveillance ranging from 22% to 74%. Among
the few previous reports from prospective studies,3–10 none
used methods adjusting for age and many did not discriminate
between the patients carrying mutations in the different MMR
genes. It is commonly agreed that CRCs may be prevented by
colonoscopy, but lacking a control group we could not calculate
what proportion this might have been. Also, the CIs of pene-
trance estimates for the mutated genes both in our and previous
studies were too wide to consider a later onset of CRC in our
study than in previous reports.
In this ﬁrst report, we did not include stage at diagnosis of
CRC and we could not determine effects of surveillance colon-
oscopy on the pathological stage at which CRCs were diag-
nosed, although early diagnosis may be a contributing factor to
the excellent long-term survival of CRC that we observed in LS
patients. When carrying out the study, we considered
<2.5 years and <3.5 years between colonoscopies as compliant
with a guideline of 2-year and 3-year intervals, respectively. As
seen in table 6, non-compliance could not explain the majority
of the CRC cases. We would like to have more information
before considering time since last colonoscopy in more detail,
and the database is currently being expanded to include stage at
diagnosis, prognosis, synchronous and para-synchronous aden-
omas and other parameters as a follow-up study based on the
current results. Meanwhile, we advocate continuation of the
existing surveillance programmes.
Some CRC in LS may have good prognosis13 and without a
control group it remains theoretically possible that the CRCs
occurring in our cohort would have been cured even without
surveillance for asymptomatic disease, but a randomised trial
denying LS patients access to colonoscopy to test such an
hypothesis is unlikely to be justiﬁable. On the other hand, the
purpose of and evidence base for ever more frequent surveil-
lance needs to be revisited, and we will expand our database to
address this issue via further studies.
Does the incidence of CRC in LS patients under surveillance
indicate that our current approach has failed or is the good sur-
vival evidence of success? For LS patients, it is of course survival
and quality of life that are the key concerns. This study shows
that the former is being achieved while assessment of the latter
will require further studies.
Adenomas in the general population are known to cause
CRC, and adenomectomy is documented to prevent CRC.14
Previous reports suggest that incidence of adenomas in LS and
late-onset colon cancer families without MMR mutations are
similar7 while the carcinogenetic process from adenoma to car-
cinoma is accelerated in LS patients.7 15 Lack of functioning
MMR genes cause microsatellite instability (MSI) and invasive
cancers in LS show MSI.16 Hyperplastic polyps in the colon of
LS patients reportedly do not show MSI,17 while adenomas
show increasing loss of MMR gene product and MSI with
increasing dysplasia.16 LS patients may also present MSI in the
crypts of a macroscopically normal gut surface.18 Thus, one
may speculate that MMR mutation carriers are capable of pro-
ducing CRC not only inside an adenoma but also independently
of a macroscopically visible adenoma, which in turn may rise
several questions: how small the invasive early cancers may be
in LS? Which is the sensitivity of colonoscopy to identify such
lesions?19 How rapidly a small preinvasive lesion may progress
to invasive cancer? Which is the time window, if any, in a prein-
vasive macroscopic detectable stage? We are currently expanding
the database to address these questions.
Our prospective results do not support major differences in
CRC incidence according to gender. Based on assumed carrier
status in former generations, differences in CRC incidence by
gender have been reported for MLH1 and MSH2,20 but these
differences were less notable in a later retrospective study
including proven carriers only.21
Figure 1 Calculated cumulative incidences by age and mutated gene
for any cancer.
Table 4 Calculated cumulative incidences for any cancer from 25, 40, 50 and 60 years of age (current age) to 70 years of age for Lynch
syndrome (LS) patients by mutated gene, in LS patients without cancer at current age in LS patients without prior or prevalent cancer at first
colonoscopy
Current age
Cumulative incidence for any first cancer from current age to 70 years by mutated gene (95% CI)
MLH1 MSH2 MSH6 PMS2
25 72% (64.7 to 78.7) 72% (61.9 to 81.2) 54% (38.6 to 68.6) 18% (0.0 to 41.0)
40 66% (57.8 to 74.2) 67% (55.8 to 77.8) 53% (38.6 to 68.6) 18% (0.0 to 41.0)
50 53% (41.9 to 63.6) 55% (40.4 to 69.0) 43% (26.4 to 60.2) 18% (0.0 to 41.0)
60 32% (17.7 to 45.4) 33% (14.4 to 51.5) 24% (5.6 to 42.2) 0% (–)
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Regarding speciﬁc genes, MSH6 carriers had later onset of
any cancer and of CRC than MLH1 and MSH2 carriers, in line
with previous reports. The low number of MSH6 and PMS2
observation years most probably represents an ascertainment
error linked to their lower penetrance22 and to the less wide-
spread availability of diagnostic testing for these genes. Also, the
age distributions may have been inﬂuenced by MSH6 mutation
carriers presenting to genetic clinics at older ages after their
relatives had already developed cancers. In spite of these uncer-
tainties, our results question current guidance that advises that
MSH6 carriers should commence colorectal surveillance at
young ages.1 2 A study of a larger cohort of young mutation car-
riers is needed to draw ﬁrm conclusions.
The higher cumulative incidence of any cancer at age 70 years
in females (75%) versus males (58%) may be a consequence of
the incidences of endometrial and ovarian cancers in females.
Endometrial cancer cumulative incidence at 70 years was con-
sistently high for MLH1 (34%), MSH2 (51%) and MSH6 (49%)
and notable in PMS2 carriers (24%). Ovarian cancer cumulative
incidence at 70 years was lower and restricted to MLH1 (11%)
and MSH2 (15%) carriers. In our series, 21/314 (7%) of the
cases identiﬁed with ﬁrst cancers had two synchronous cancers
in different organs, suggesting that the risk of getting a new
primary cancer may be increased in those having already had
one or more cancers or precursor lesions1 2 There is limited
prospectively observed evidence, however, on the magnitude of
such risks. The methods used in this study are not suitable for
calculation of these risks. Neither does our study provide infor-
mation on cancer risks in LS patients under 25 years of age. As
the clinical guidelines used in our collaborating centres suggest
starting surveillance at this age, we could not consider AIR for
younger patients. Because colonoscopic surveillance did not
prevent all CRC in MLH1 and MSH2 carriers, it is unlikely that
it did so in MSH6 and PMS2 carriers. Our ﬁndings make it very
unlikely that MSH6 or PMS2 mutation carriers develop a signiﬁ-
cant number of LS-associated cancers before 25 years, but a
small proportion of MLH1 and MHS2 mutation carriers may do
so. Our results have no bearing on the current guidelines that
Table 5 Calculated cumulative cancer incidences from 25 to 40, 50, 60 or 70 years of age for any cancer and for selected groups of cancers
occurring as first cancer, by gender and by mutated gene
Selected group Age (years)
Calculated cumulative cancer incidence to given age (95% CI) by group and mutated gene
MLH1 MSH2 MSH6 PMS2
Any cancer, males and females 40 17% (12.2 to 21.3) 14% (8.3 to 20.3) 0% (–) 0% (–)
50 40% (34.7 to 45.7) 37% (29.4 to 45.1) 18% (8.0 to 28.3) 0% (–)
60 59% (52.8 to 64.6) 58% (49.3 to 65.9) 39% (25.8 to 52.2) 18% (0.0 to 41.0)
70 72% (64.7 to 78.7) 72% (61.9 to 81.2) 54% (38.6 to 68.6) 18% (0.0 to 41.0)
Any cancer, males 40 19% (12.1 to 25.8) 8% (1.2 to 14.3) 0% (–) 0% (–)
50 40% (31.7 to 47.7) 25% (14.3 to 35.5) 15% (0.0 to 31.3) 0% (–)
60 55% (46.7 to 64.4) 47% (33.3 to 60.8) 25% (6.0 to 44.5) 0% (–)
70 59% (49.7 to 68.6) 71% (52.7 to 89.8) 31% (10.3 to 52.3) 0% (to)
Any cancer, females 40 14% (8.4 to 20.5) 20% (10.6 to 29.7) 0% (–) 0% (–)
50 41% (32.9 to 48.0) 47% (36.2 to 57.8) 20% (6.9 to 33.6) 0% (–)
60 61% (53.2 to 68.8) 67% (56.6 to 77.0) 48% (30.5 to 65.6) 24% (0.0 to 53.2)
70 80% (71.2 to 88.8) 75% (64.5 to 85.6) 71% (51.8 to 90.5) 24% (0.0 to 53.2)
CRC, males and females 40 14% (10.0 to 18.7) 9% (4.2 to 14.1) 0% (–) 0% (–)
50 27% (22.2 to 32.7) 18% (11.4 to 24.4) 2% (0.0 to 5.6) 0% (–)
60 37% (31.0 to 43.4) 24% (16.1 to 32.0) 10% (0.5 to 19.6) 0% (–)
70 46% (37.1 to 54.1) 35% (22.4 to 47.1) 20% (4.4 to 35.4) 0% (–)
CRC, males 40 17% (10.3 to 23.5) 8% (1.2 to 14.3) 0% (–) 0% (–)
50 33% (25.5 to 41.4) 16% (6.7 to 24.5) 0% (–) 0% (–)
60 44% (35.3 to 53.1) 26% (18.7 to 44.2) 6% (0.0 to 18.8) 0% (–)
70 47% (36.9 to 56.1) 37% (19.5 to 53.6) 14% (0.0 to 32.2) 0% (–)
CRC, females 40 11% (6.2 to 17.5) 11% (3.1 to 18.3) 0% (–) 0% (–)
50 21% (14.6 to 28.3) 20% (10.6 to 29.6) 3% (0.0 to 9.8) 0% (–)
60 30% (21.9 to 38.9) 22% (12.2 to 32.5) 12% (0.0 to 25.9) 0% (–)
70 45% (31.1 to 59.3) 33% (16.3 to 48.9) 26% (0.0 to 54.2) 0% (–)
Endometrial cancer, females 40 3% (0.1 to 5.9) 2% (0.0 to 4.7) 0% (–) 0% (–)
50 18% (11.3 to 24.7) 15% (6.0 to 24.6) 16% (3.1 to 28.6) 0% (–)
60 34% (24.2 to 44.3) 44% (29.3 to 58.2) 40% (19.5 to 61.4) 24% (0.0 to 52.8)
70 34% (24.2 to 44.3) 51% (32.7 to 69.2) 49% (25.3 to 73.5) 24% (0.0 to 52.8)
Ovarian cancer, females 40 1% (0.0 to 3.6) 4% (0.0 to 8.9) 0% (–) 0% (–)
50 7% (2.2 to 11.2) 12% (4.2 to 20.2) 0% (–) 0% (–)
60 9% (2.9 to 13.2) 15% (5.5 to 24.4) 0% (–) 0% (–)
70 11% (3.2 to 19.8) 15% (5.5 to 24.4) 0% (–) 0% (–)
Upper GI cancer; males and females 40 0.4% (0.0 to 1.1) 0% (−) 0%(–) 0% (–)
50 2% (0.5 to 4.1) 3% (0.0 to 5.7) 0%(–) 0% (–)
60 7% (2.4 to 10.4) 5% (0.6 to 10.5) 2% (0.0 to 6.3) 0% (–)
70 18% (7.2 to 27.6) 5% (0.6 to 10.5) 2% (0.0 to 6.3) 0% (–)
Urinary tract cancer; males and females 40 0% (−) 0% (−) 0% (–) 0% (–)
50 1% (0.0 to 2.2) 1% (0.0 to 2.3) 4% (0.0 to 9.4) 0% (–)
60 2% (0.0 to 3.3) 7% (1.8 to 15.1) 4% (0.0 to 9.4) 0% (–)
70 2% (0.0 to 3.3) 20% (4.1 to 33.9) 9% (0.0 to 19.3) 0% (–)
Cancers included were colorectal (CRC), endometrial, ovarian, upper GI (including gastric, pancreatic, biliary tract and duodenal cancers) and urinary tract cancers (including kidney,
calyx, ureter and urinary bladder) in LS patients without prior or prevalent cancer at first colonoscopy.
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suggest surveillance only after age 25 years for MLH1 and
MSH2 mutation carriers.
The three major LS-associated cancer types, CRC, endomet-
rial and ovarian, all had excellent observed survival, which is
very encouraging for carriers of MMR gene mutations. Further
investigation will be needed to determine the degree to which
this good prognosis is the result of early detection due to sur-
veillance, improved prognosis due to detection at early stages,
lead time bias due to early detection and/or represents a better
prognosis for cancers in LS patients than for cancers arising in
the general population. Relevant factors might include the high
degree of immunogenicity and paucity of progressive metastatic
disease in LS CRCs13 23 and the efﬁcacy of current treatments
in the patient group.
Most ovarian cancers in LS were cured, consistent with our
previous study,22 and the same was true for endometrial
cancers. Also, our ﬁndings support the notion that LS ovarian
cancers have a good prognosis when given current
treatment.24 25 This good prognosis may be partly the result of
early detection due to surveillance, but pathological and
molecular genetic analysis have also indicated more favourable
tumour characteristics in LS-associated ovarian cancers com-
pared with sporadic disease.26 27 This is in sharp contrast to
BRCA1/2 ovarian cancer cases that have a poor prognosis
despite early detection and treatment.28 The cumulative inci-
dence for ovarian cancer in MLH1 and MSH2 carriers up to
50 years of age was similar to reported cumulative incidence in
BRCA1 carriers28 but with lower incidence later in life. The
ﬁnding that ovarian cancer was restricted to MLH1 and MSH2
mutation carriers was unexpected and needs validation.
Certain characteristics of the methods we used need to be
highlighted. The calculation of cumulative incidence by age is
based upon the observed point estimates for annual incidence
for each age group. The method adjusts for uneven distribution
of numbers in the different age groups, and for the different dis-
tributions of ages of patients by mutated gene. If we had esti-
mated penetrance by gene from inclusion to last observation
using the Kaplan–Meier algorithm, equal AIR in all age groups
had to be assumed for each gene. If doing so, we would have
compared younger MLH1/MSH2 carriers to older MSH6/PMS2
carriers. Assimilating our data into one larger database was man-
datory to arrive at sufﬁcient numbers to use our method to cal-
culate AIR by age and thereby estimate cumulative incidences by
age, mutated gene and gender. If doing so, we avoided many
ascertainment and time-trend biases present in retrospective
family studies that were previously used to determine
Figure 2 Calculated cumulative incidences by age and mutated gene
for colorectal cancer (CRC) as the ﬁrst cancer.
Figure 3 Calculated cumulative incidences by age and mutated gene
for endometrial cancer as the ﬁrst cancer by gene.
Table 6 Time since last colonoscopy in months; and number,
cumulative number and cumulative % of colorectal cancer (CRC)
cases diagnosed in each time interval
Months since last
colonoscopy
Number of
cases
Cumulative number
of cases
Cumulative
%
0–5 0 0 0
6–11 9 9 6
12–17 23 32 22
18–23 13 45 31
24–29 39 84 58
30–35 10 94 65
36–41 21 115 79
42–59 18 133 92
60–125 12 145 100
Six cases counted once here had two synchronous CRCs, cf table 2 showing 151 CRC
diagnoses.
Table 7 5-year and 10-year crude survival after first cancer
diagnosed by cancer type in Lynch syndrome (LS) patients without
prior or prevalent cancer at first colonoscopy
Group
Number
cases
5-year survival
(95% CI)
10-year survival
(95% CI)
Any cancer 301 90% (86 to 93) 87% (83 to 91)
Colorectal cancer 140 94% (90 to 98) 91% (84 to 95)
Endometrial cancer 71 98% (88 to 99.8) 98% (88 to 99.8)
Ovarian cancer 19 88% (60 to 97) 89% (60 to 97)
Upper GI cancer 24 58% (36 to 75) 53% (31 to 71)
Urinary tract cancer 17 82% (51 to 93) 73% (42 to 89)
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penetrance, and patient numbers were sufﬁcient to adjust for
skewed distributions by age and mutated gene.
In spite of the strengths, this study has some limitations. The
cumulative incidences presented are not cumulative incidences
for organ-speciﬁc cancers, but for any ﬁrst cancers and for the
organ in which the ﬁrst cancers occurred. Calculation of cumu-
lative incidence by age for speciﬁc cancers irrespective of the
occurrence of other cancers will need a different data set and
speciﬁc methods, and the database is currently being expanded
to do so. The long period (>20 years) of observation is likely to
span improvements in techniques for early diagnosis of cancer,
as well as treatment, both of which may improve survival.
Assuming that shorter time between colonoscopies and/or that
recent treatment is possibly better than the average during the
period reported, our results may be considered worst-case
estimates.
The information provided here should help in the genetic
counselling of individual patients. We have made it available via
an interactive open access website for personalised healthcare at
http://www.LScarisk.org. Based on the algorithm given above
and the information given in online supplementary table S1, the
website calculates the cumulative risk of developing cancer from
any age selected by the user to any age up to 70 years for any
currently unaffected patient with LS by entering age, gender
and mutated gene. The website may be used for any single
patient to provide personalised risk estimates for all groups of
cancers detailed in table 5.
The ﬁndings presented here raise a number of questions that
will be addressed by further studies: the effects of colonoscopy
intervals on CRC incidence; whether or not CRC in LS may
emerge outside a macroscopic visible adenoma, time to subse-
quent cancer in LS patients surviving their ﬁrst cancers; the life-
time risk for any speciﬁc cancer in those surviving the other
cancer types; the disease-speciﬁc survival for all distinct cancer
types; and investigation of the penetrance and expression of dif-
ferent classes of mutations at each MMR gene locus. We are cur-
rently expanding the database to address these key questions. As
the numbers of young MSH6 or PMS2 mutation carriers we have
been able to include have been limited so far, we welcome other
parties with such series to join us and contribute to future reﬁne-
ment of incidence rates for MSH6 and PMS2 mutation carriers.
For further information on the collaborating activities, please
visit http://insight-group.org/ and http://mallorca-group.eu/. To
tailor cancer risk prediction according to a given patient’s age,
gender and mutated gene, visit http://LsCaRisk.org.
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